they have revenue growth. Markets will support as it strengthens...

they have revenue growth. Markets will support as it strengthens to bridge any cash flow gap before critical mass is achieved imo.

How many surgeons, are now repeat customers for their continuous stream of patients ?
Then the market will look at a superior product will strengthen utilization from referrals as a better standard of care.

Anything which has established mature market demand, a forward growth curve that is organic, a great product, superior, and therefor only requires the time for it to reach critical mass of revenues displacing of inferior tech, to exceed the cost of marketing and corporate overheads, should eventually break out to a success story.

This is an ideal time to pick up imo, where the growth is being demonstrated, and the valuation is just a micro cap.
If the next Quarter shows continued momentum in sales, then is demonstrating that momentum of surgeon patient awareness and adoption.

Not investment advice.